This company listing is no longer active
TBP Stock Overview
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tetra Bio-Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.075 |
| 52 Week Low | CA$0.015 |
| Beta | 2.26 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -58.33% |
| 3 Year Change | -88.64% |
| 5 Year Change | -96.48% |
| Change since IPO | 0% |
Recent News & Updates
Shareholder Returns
| TBP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -8.4% | -1.4% |
| 1Y | -58.3% | 52.3% | 4.7% |
Return vs Industry: TBP underperformed the Canadian Pharmaceuticals industry which returned -55.8% over the past year.
Return vs Market: TBP underperformed the Canadian Market which returned -6.6% over the past year.
Price Volatility
| TBP volatility | |
|---|---|
| TBP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 14.3% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.6% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: TBP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TBP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 33 | Guy Chamberland | www.tetrabiopharma.com |
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.
Tetra Bio-Pharma Inc. Fundamentals Summary
| TBP fundamental statistics | |
|---|---|
| Market cap | CA$12.89m |
| Earnings (TTM) | -CA$39.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs TBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBP income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$39.02m |
| Earnings | -CA$39.02m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -28.1% |
How did TBP perform over the long term?
See historical performance and comparison